 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Nicholas Foreman and Angela Pierce.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.911 |
|
|
|
-
Pierce AM, Witt DA, Donson AM, Gilani A, Sanford B, Sill M, Van Court B, Oweida A, Prince EW, Steiner J, Danis E, Dorris K, Hankinson T, Handler MH, Jones KL, Karam SD, Serkova NJ, Vibhakar R, Foreman NK, Griesinger AM. Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma. Neuro Oncol. 2019 12 17; 21(12):1540-1551.
Score: 0.170
-
Sobral LM, Walker FM, Madhavan K, Janko E, Donthula S, Danis E, Bompada P, Balakrishnan I, Wang D, Pierce A, Haag MM, Carstens BJ, Serkova NJ, Foreman NK, Venkataraman S, Veo B, Vibhakar R, Dahl NA. Targeting processive transcription for Myc-driven circuitry in medulloblastoma. Neuro Oncol. 2025 May 15.
Score: 0.062
-
Martin Sobral L, Walker FM, Madhavan K, Janko E, Donthula S, Balakrishnan I, Wang D, Pierce A, Haag MM, Carstens BJ, Serkova NJ, Foreman NK, Venkataraman S, Veo B, Vibhakar R, Dahl NA. Targeting processive transcription for Myc-driven circuitry in medulloblastoma. bioRxiv. 2025 Mar 17.
Score: 0.061
-
Alimova I, Wang D, DeSisto J, Danis E, Lakshmanachetty S, Prince E, Murdock G, Pierce A, Donson A, Balakrishnan I, Serkova N, Lin H, Foreman NK, Dahl N, Venkataraman S, Vibhakar R. SIRT2 regulates the SMARCB1 loss-driven differentiation block in ATRT. Mol Cancer Res. 2025 Feb 17.
Score: 0.061
-
Walker FM, Sobral LM, Danis E, Sanford B, Donthula S, Balakrishnan I, Wang D, Pierce A, Karam SD, Kargar S, Serkova NJ, Foreman NK, Venkataraman S, Dowell R, Vibhakar R, Dahl NA. Rapid P-TEFb-dependent transcriptional reorganization underpins the glioma adaptive response to radiotherapy. Nat Commun. 2024 May 30; 15(1):4616.
Score: 0.058
-
Griesinger AM, Calzadilla AJ, Grimaldo E, Donson AM, Amani V, Pierce AM, Steiner J, Kargar S, Serkova NJ, Bertrand KC, Wright KD, Vibhakar R, Hankinson T, Handler M, Lindsay HB, Foreman NK, Dorris K. Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma. Clin Cancer Res. 2024 Apr 15; 30(8):1544-1554.
Score: 0.057
-
Walker FM, Sobral LM, Danis E, Sanford B, Balakrishnan I, Wang D, Pierce A, Karam SD, Serkova NJ, Foreman NK, Venkataraman S, Dowell R, Vibhakar R, Dahl NA. Rapid PTEFb-dependent transcriptional reorganization underpins the glioma adaptive response to radiotherapy. bioRxiv. 2023 Jan 25.
Score: 0.053
-
Wang D, Veo B, Pierce A, Fosmire S, Madhavan K, Balakrishnan I, Donson A, Alimova I, Sullivan KD, Joshi M, Erlander M, Ridinger M, Foreman NK, Venkataraman S, Vibhakar R. A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy. Neuro Oncol. 2022 03 12; 24(3):414-426.
Score: 0.050
-
Alimova I, Wang D, Danis E, Pierce A, Donson A, Serkova N, Madhavan K, Lakshmanachetty S, Balakrishnan I, Foreman NK, Mitra S, Venkataraman S, Vibhakar R. Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors. Int J Oncol. 2022 Mar; 60(3).
Score: 0.049
-
Balakrishnan I, Danis E, Pierce A, Madhavan K, Wang D, Dahl N, Sanford B, Birks DK, Davidson N, Metselaar DS, Meel MH, Lemma R, Donson A, Vijmasi T, Katagi H, Sola I, Fosmire S, Alimova I, Steiner J, Gilani A, Hulleman E, Serkova NJ, Hashizume R, Hawkins C, Carcaboso AM, Gupta N, Monje M, Jabado N, Jones K, Foreman N, Green A, Vibhakar R, Venkataraman S. Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG. Cell Rep. 2020 10 20; 33(3):108286.
Score: 0.045
-
Dahl NA, Danis E, Balakrishnan I, Wang D, Pierce A, Walker FM, Gilani A, Serkova NJ, Madhavan K, Fosmire S, Green AL, Foreman NK, Venkataraman S, Vibhakar R. Super Elongation Complex as a Targetable Dependency in Diffuse Midline Glioma. Cell Rep. 2020 04 07; 31(1):107485.
Score: 0.043
-
Moreira DC, Venkataraman S, Subramanian A, Desisto J, Balakrishnan I, Prince E, Pierce A, Griesinger A, Green A, Eberhardt CG, Foreman NK, Vibhakar R. Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine. J Neurooncol. 2020 May; 147(3):531-545.
Score: 0.043
-
Green AL, Flannery P, Hankinson TC, O'Neill B, Amani V, DeSisto J, Knox A, Chatwin H, Lemma R, Hoffman LM, Mulcahy Levy J, Raybin J, Hemenway M, Gilani A, Koschmann C, Dahl N, Handler M, Pierce A, Venkataraman S, Foreman N, Vibhakar R, Wempe MF, Dorris K. Preclinical and clinical investigation of intratumoral chemotherapy pharmacokinetics in DIPG using gemcitabine. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa021.
Score: 0.043
-
Alimova I, Pierce A, Danis E, Donson A, Birks DK, Griesinger A, Foreman NK, Santi M, Soucek L, Venkataraman S, Vibhakar R. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo. Int J Cancer. 2019 04 15; 144(8):1983-1995.
Score: 0.040
-
Veo B, Danis E, Pierce A, Sola I, Wang D, Foreman NK, Jin J, Ma A, Serkova N, Venkataraman S, Vibhakar R. Combined functional genomic and chemical screens identify SETD8 as a therapeutic target in MYC-driven medulloblastoma. JCI Insight. 2019 Jan 10; 4(1).
Score: 0.040
-
Alimova I, Pierce AM, Harris P, Donson A, Birks DK, Prince E, Balakrishnan I, Foreman NK, Kool M, Hoffman L, Venkataraman S, Vibhakar R. Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor. Oncotarget. 2017 Nov 14; 8(57):97290-97303.
Score: 0.037
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|